GSK PLC Sponsored ADR (NYSE:GSK) Stock Has Average Target Price of $55.33

GSK PLC Sponsored ADR (NYSE:GSK) has earned an average recommendation of “Hold” from the nineteen analysts that are covering the company, MarketBeat reports. Three analysts have rated the stock with a sell rating, twelve have assigned a hold rating and four have issued a buy rating on the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $55.33.

Several research analysts recently commented on the company. Wall Street Zen cut GSK from a “buy” rating to a “hold” rating in a research note on Saturday, August 1st. Barclays restated a “sell” rating on shares of GSK in a report on Monday, September 7th. Morgan Stanley reaffirmed an “underweight” rating on shares of GSK in a research report on Tuesday, August 25th. Wolfe Research began coverage on GSK in a research note on Friday, October 9th. They issued an “outperform” rating and a $70.00 price objective for the company. Finally, Sanford C. Bernstein reissued a “buy” rating on shares of GSK in a research report on Sunday, August 2nd.

Institutional Trading of GSK

Institutional investors and hedge funds have recently made changes to their positions in the company. Royal Fund Management LLC boosted its stake in GSK by 5.1% during the 3rd quarter. Royal Fund Management LLC now owns 37,952 shares of the pharmaceutical company’s stock worth $1,828,000 after purchasing an additional 1,833 shares during the period. Brookstone Capital Management grew its position in GSK by 5.4% during the 3rd quarter. Brookstone Capital Management now owns 40,002 shares of the pharmaceutical company’s stock worth $1,927,000 after purchasing an additional 2,042 shares during the last quarter. Ledyard National Bank grew its position in GSK by 2.8% during the 3rd quarter. Ledyard National Bank now owns 49,552 shares of the pharmaceutical company’s stock worth $2,387,000 after purchasing an additional 1,339 shares during the last quarter. NBT Bank N.A. acquired a new position in GSK in the third quarter valued at $929,000. Finally, Root Financial Partners LLC acquired a new position in GSK in the third quarter valued at $158,000. 15.74% of the stock is owned by hedge funds and other institutional investors.

More GSK News

Here are the key news stories impacting GSK this week:

• Positive Sentiment: The FDA approved Hibsago for chronic hepatitis B in adults without cirrhosis. The treatment is being described as the first functional cure in this market, giving GSK a potentially differentiated commercial product and expanding its growth pipeline. FDA approves GSK’s Hibsago as first functional cure for hepatitis B
• Positive Sentiment: Jefferies reiterated its Buy rating and 2,500p price target, saying the Hibsago approval supports a potential £2.2 billion sales forecast. The broker’s target implies substantial upside from its reference price, strengthening the bullish case for GSK. GSK hepatitis B drug approval supports £2.2bn sales forecast
• Positive Sentiment: Coverage of the GSK-Ionis hepatitis B program suggests the functional-cure market could create a significant new commercial opportunity and attract follow-on competitors, highlighting the potential scale of the treatment category. GSK, Ionis hepatitis B functional cure breaks open market for followers
• Positive Sentiment: GSK and Mubadala Bio’s IDS announced a strategic partnership, potentially expanding collaboration and business-development opportunities in biotechnology. Specific financial terms were not provided. Mubadala Bio’s IDS and GSK sign strategic partnership
• Neutral Sentiment: GSK executive Deborah Waterhouse was selected as CSL’s next CEO. The move may represent a modest talent-loss concern for GSK, but it does not directly change the company’s financial outlook. CSL Names GSK Veteran Waterhouse CEO
• Neutral Sentiment: HUTCHMED completed the closing of its agreement granting GSK exclusive development and licensing rights outside China for a KRAS-EGFR antibody-drug conjugate. The deal broadens GSK’s oncology pipeline, although the reported update supplied no new financial terms. HUTCHMED Announces Closing of KRAS-EGFR License to GSK
• Negative Sentiment: Analysts expect GSK to report a year-over-year earnings decline in its upcoming quarterly results, creating a near-term risk that the company could miss expectations or issue cautious commentary. Analysts Estimate GSK to Report a Decline in Earnings

GSK Stock Up 2.3%

GSK stock opened at $51.18 on Tuesday. The firm has a market cap of $103.52 billion, a PE ratio of 10.51, a PEG ratio of 2.25 and a beta of 0.33. The company has a debt-to-equity ratio of 0.81, a quick ratio of 0.52 and a current ratio of 0.82. The firm’s 50 day moving average price is $49.56 and its 200-day moving average price is $51.46. GSK has a one year low of $42.85 and a one year high of $61.69.

GSK (NYSE:GSK) last issued its quarterly earnings data on Tuesday, July 28th. The pharmaceutical company reported $1.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.27 by $0.09. GSK had a net margin of 14.56% and a return on equity of 43.23%. The firm had revenue of $11.14 billion for the quarter, compared to analyst estimates of $11.02 billion. During the same period in the previous year, the firm earned $0.47 EPS. GSK’s revenue was up 5.3% on a year-over-year basis. GSK has set its FY 2026 guidance at 4.900-5.000 EPS. On average, equities research analysts anticipate that GSK will post 4.78 EPS for the current year.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, October 8th. Stockholders of record on Friday, August 14th were given a dividend of $0.4515 per share. The ex-dividend date was Friday, August 14th. This represents a $1.81 annualized dividend and a dividend yield of 3.5%. This is a boost from GSK’s previous quarterly dividend of $0.44. GSK’s payout ratio is presently 55.31%.

GSK Company Profile

GSK plc, formerly GlaxoSmithKline, is a global biopharmaceutical company headquartered in Brentford, England. The company focuses on researching, developing and commercializing medicines and vaccines designed to prevent and treat infectious diseases, respiratory conditions, immune-related disorders and certain cancers.

Its vaccine portfolio includes products such as Shingrix for shingles, Arexvy for respiratory syncytial virus (RSV) in older adults, and vaccines targeting meningitis, influenza and other infectious diseases.